Skip to content

clinical study of Dhatriyadi Anjana in Simple Myopia

A clinical study to assess the efficacy of Dhatriyadi Anjana in Simple Myopia

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/034948
Enrollment
110
Registered
2021-07-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H521- Myopia

Interventions

Intervention1: Dhatriyadi Anjana and Myopic Glasses: Dhatriyadi Anjana 125 mg 12 hrly (Twice daily) will be applied topically (In Conjunctival Cul-de-Sac on the medial side of the lower palpebral conj

Sponsors

Bharti Vidyapeeth Deemed to be university
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients presenting with classical features of Simple myopia will be selected irrespective of Gender, Occupation, religion etc. 2.Patients aged between 12 to 40 years 3.Patients having simple Myopia (-0.50 DS to -2.0 DS)

Exclusion criteria

Exclusion criteria: 1.Hypermetropia, Astigmatism, Presbyopia. 2.Simple Myopia ( >2.0 DS), Pathological Myopia. 3.Patient with any systemic disease like HTN, DM, TB etc. 4.Patient with any other ocular pathology like Cataract, Glaucoma, retinal pathology etc. 5.Functional Myopia 6.If the both the parent of the subject are myopic 7.Pregnant and Lactating Mother.

Design outcomes

Primary

MeasureTime frame
Reduction in myopic correction equal or more than 0.25DTimepoint: 60 days

Secondary

MeasureTime frame
Relief in Sign and Symptoms of the MyopiaTimepoint: 60 days

Countries

India

Contacts

Public ContactDr Santosh Shivaji Mulik

College of Ayurveda, Bharti Vidyapeeth (DU)

drsantoshmulik@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026